Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes.
Lue JK, Luttwak E, Rivas-Delgado A, Irawan H, Boardman A, Caron PC, David K, Epstein-Peterson Z, Falchi L, Ghione P, Hamlin P, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Moskowitz A, Noy A, Palomba ML, Steiner R, Stuver R, Torka P, Vardhana S, Zelenetz AD, Schoder H, Imber B, Yahalom J, Zhang Y, Galera P, Dogan A, Aypar U, Salles G. Lue JK, et al. Among authors: boardman a. Blood Cancer J. 2024 Oct 14;14(1):178. doi: 10.1038/s41408-024-01148-x. Blood Cancer J. 2024. PMID: 39402034 Free PMC article. No abstract available.
CAR T-cell therapy in large B cell lymphoma.
Boardman AP, Salles G. Boardman AP, et al. Hematol Oncol. 2023 Jun;41 Suppl 1(Suppl 1):112-118. doi: 10.1002/hon.3153. Hematol Oncol. 2023. PMID: 37294963 Free PMC article. Review.
Does BTKi improve CAR T-cell therapy in MCL?
Boardman AP, Palomba ML. Boardman AP, et al. Blood. 2024 Feb 22;143(8):653-655. doi: 10.1182/blood.2023022898. Blood. 2024. PMID: 38386430 No abstract available.
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.
Cederquist GY, Schefflein J, Devlin SM, Shah GL, Shouval R, Hubbeling H, Tringale K, Alarcon Tomas A, Fregonese B, Hajj C, Boardman A, Luna De Abia A, Corona M, Cassanello G, Dahi PB, Lin RJ, Ghione P, Salles G, Perales MA, Palomba ML, Falchi L, Scordo M, Grommes C, Yahalom J, Imber BS. Cederquist GY, et al. Among authors: boardman a. Blood Adv. 2024 Oct 8;8(19):5192-5199. doi: 10.1182/bloodadvances.2024013393. Blood Adv. 2024. PMID: 38861344 Free PMC article.
Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma.
Hubbeling H, Leithner D, Silverman EA, Flynn J, Devlin S, Shah G, Fregonese B, Wills B, Bedmutha A, Alarcon Tomas A, Parascondola A, Saldia A, Landego I, Hajj C, Boardman AP, Dahi PB, Ghosh A, Giralt S, Lin RJ, Park J, Scordo M, Salles G, Yahalom J, Palomba ML, Schöder H, Perales MA, Shouval R, Imber BS. Hubbeling H, et al. Among authors: boardman ap. Clin Cancer Res. 2024 Nov 15;30(22):5083-5093. doi: 10.1158/1078-0432.CCR-24-0830. Clin Cancer Res. 2024. PMID: 39259292
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes.
Valtis YK, Devlin S, Shouval R, Rejeski K, Corona M, Luna De Abia A, Rivas-Delgado A, Luttwak E, Cassanello G, Landego I, Schöder H, Bedmutha A, Boardman A, Shah GL, Scordo M, Perales MA, Salles G, Palomba ML, Shah UA, Park JH. Valtis YK, et al. Among authors: boardman a. Blood Adv. 2025 Jan 14;9(1):151-161. doi: 10.1182/bloodadvances.2024014555. Blood Adv. 2025. PMID: 39471490
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy.
Boardman AP, Gutgarts V, Flynn J, Devlin SM, Goldman A, Tomas AA, Fein JA, Slingerland JB, Parascondola A, Lin RJ, Scordo M, Dahi PB, Giralt S, Palomba ML, Salles G, Nath K, Walji M, Corona M, Park JH, Shah GL, Perales MA, Jaffer-Sathick I, Shouval R. Boardman AP, et al. Haematologica. 2024 Nov 21. doi: 10.3324/haematol.2024.286021. Online ahead of print. Haematologica. 2024. PMID: 39568416 Free article.
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
Torka P, Feldman T, Savage KJ, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Capadona C, Subzwari S, Galasso N, Yang J, Post M, Boardman A, Caron P, David K, Epstein-Peterson Z, Falchi L, Ghione P, Hamlin P, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Lue J, Noy A, Owens C, Palomba ML, Salles GA, Steiner R, Stuver R, Vardhana S, Yahalom J, Dogan A, Zelenetz AD, Schöder H, Moskowitz AJ. Torka P, et al. Among authors: boardman a. J Clin Oncol. 2024 Dec 11:JCO2401278. doi: 10.1200/JCO-24-01278. Online ahead of print. J Clin Oncol. 2024. PMID: 39661923
Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors.
James SE, Chen S, Ng BD, Fischman JS, Jahn L, Boardman AP, Rajagopalan A, Elias HK, Massa A, Manuele D, Nichols KB, Lazrak A, Lee N, Roche AM, McFarland AG, Petrichenko A, Everett JK, Bushman FD, Fei T, Kousa AI, Lemarquis AL, DeWolf S, Peled JU, Vardhana SA, Klebanoff CA, van den Brink MRM. James SE, et al. Among authors: boardman ap. Nat Biomed Eng. 2024 Dec;8(12):1592-1614. doi: 10.1038/s41551-024-01287-3. Epub 2024 Dec 23. Nat Biomed Eng. 2024. PMID: 39715901
112 results